Tempest Therapeutics
TPST
Tempest Therapeutics (TPST) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$2.07
- EPS estimate
- −$3.23
- EPS surprise
- +35.91%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 11, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 11, 2025 | −$3.23 | −$2.07 | +35.91% | $0.00 | SEC |
| Q1 2025 | May 13, 2025 | −$3.29 | −$3.16 | +4.05% | $0.00 | SEC |
| Q4 2024 | Mar 27, 2025 | −$3.27 | −$4.03 | −23.08% | $0.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$4.71 | −$5.33 | −13.26% | $0.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$5.24 | −$5.46 | −4.18% | $0.00 | SEC |
| Q1 2024 | May 9, 2024 | −$5.23 | −$4.68 | +10.57% | $0.00 | SEC |
| Q4 2023 | Mar 19, 2024 | −$5.03 | −$4.94 | +1.86% | $0.00 | SEC |
| Q3 2023 | Nov 8, 2023 | −$7.45 | −$6.24 | +16.24% | $0.00 | SEC |
| Q2 2023 | Aug 10, 2023 | −$6.73 | −$7.02 | −4.35% | $0.00 | SEC |
| Q1 2023 | May 10, 2023 | −$8.35 | −$7.15 | +14.40% | $0.00 | SEC |
| Q4 2022 | Mar 22, 2023 | −$9.88 | −$7.28 | +26.35% | $0.00 | SEC |
| Q3 2022 | Nov 8, 2022 | −$10.43 | −$8.58 | +17.76% | $0.00 | SEC |
| Q2 2022 | Aug 15, 2022 | −$10.27 | −$10.27 | +0.00% | $0.00 | SEC |
| Q1 2022 | May 13, 2022 | −$14.52 | −$15.34 | −5.67% | $0.00 | SEC |
| Q4 2021 | Mar 29, 2022 | −$16.03 | −$14.56 | +9.19% | $0.00 | SEC |
| Q3 2021 | Nov 10, 2021 | −$13.61 | −$15.73 | −15.60% | $0.00 | SEC |
| Q2 2021 | Aug 12, 2021 | −$11.38 | −$99.19 | −772.00% | $0.00 | SEC |
| Q4 2020 | Mar 29, 2021 | −$66.30 | −$74.10 | −11.76% | $0.00 | — |
| Q3 2020 | Nov 9, 2020 | −$89.70 | −$66.30 | +26.09% | $0.00 | — |
| Q2 2020 | Aug 10, 2020 | −$106.60 | −$109.20 | −2.44% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Tempest Therapeutics (TPST) last report earnings?
Tempest Therapeutics last reported on Aug 11, 2025, covering fiscal Q2 2025.
Did TPST beat earnings estimates?
Yes. Tempest Therapeutics reported EPS of −$2.07 for Q2 2025 against a −$3.23 estimate — a 35.91% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.